Study Details
Design, interventions, and primary outcomes
About This Study
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Design
Interventions / Regimen
- Drug: M7437 — Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.
- Drug: M7437 — Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.
Primary Outcomes
- Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs) (DLT period is 21 days (cycle 1))
- Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs) (Up to end of Part 1 of study (approximately 1 year 8 months))
Phase: PHASE1
Status: Recruiting
Start Date: 2026-02-13
Completion: 2029-03-28
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Collaborators: Merck KGaA, Darmstadt, Germany
- Medical Responsible (STUDY_DIRECTOR) - EMD Serono Research & Development Institute, Inc.
- Drug: M7437 — Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.
- Drug: M7437 — Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.